Use of the New Proliferation Signal Inhibitor Everolimus in Renal Transplant Patients in Spain: Preliminary Results of the EVERODATA Registry

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2157-2159

  Ruiz, J C ^a   Sanchez A ^b   Rengel, M ^c   Beneyto, I ^d   Plaza, J J ^e   Zarraga S ^f   Errasti, P ^g   Andres A ^h   Morales, J M ^h   Torregrosa, J V ⁱ   Alarcon A ^j   Morey, A ^j   Romero, R ^k   Fernandez A ^l   Diaz J M ^m   Cantarell, C ⁿ  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ H Clinic i Provincial   (Spain)

^j Son Dureta Children's Hospital   (Spain)

^k H S Clínico de Santiago   (Spain)

^l Servicio de Anatomía Patológica Hospital   (Spain)

^m FUNDACIÓ PUIGVERT   (Spain)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA;

ADULT; AGED; CALCINEURIN; CELL DIVISION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS; SPAIN;

EID: 34548689882     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.07.071     Document Type: Article

References (3)

1. Tedesco-Silva Jr. H., Vitko S., Pascual J., et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 20 (2007) 27
2. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626
3. Ruiz J.C., Sanchez-Fructuoso A., Rodrigo E., et al. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. Transplant Proc 38 (2006) 2424